EWM
VRTX icon

Executive Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Executive Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-90
Closed -$15K – 948
2018
Q4 		$15K Buy
+90
New +$15.6K ﹤0.01% 490

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Executive Wealth Management's VRTX Position: Q1 2019 in Review

Executive Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2019, closing a stake of 90 shares — an estimated $15K sold.

Executive Wealth Management first reported a position in VRTX in Q4 2018 and held it in 1 quarter. The position peaked at $15K in Q4 2018. 736 funds tracked by Wall St. Rank hold VRTX as of Q1 2019.

  • Executive Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Executive Wealth Management sold 90 Vertex Pharmaceuticals shares in Q1 2019, an estimated $15K.
  • Executive Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Executive Wealth Management's Vertex Pharmaceuticals position peaked at $15K in Q4 2018.
  • 736 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2019.

Based on Executive Wealth Management's 13F filing for Q1 2019, filed 2 May 2019.